Top

Published in:

Open Access 01-12-2009 | Review

New targets for the treatment of follicular lymphoma

Authors: Nishant Tageja, Subhash Padheye, Prasad Dandawate, Ayad Al-Katib, Ramzi M Mohammad

Published in: Journal of Hematology & Oncology | Issue 1/2009

Abstract

The last two decades have witnessed striking advances in our understanding of the biological factors underlying the development of Follicular lymphoma (FL). Development of newer treatment approaches have improved the outlook for many individuals with these disorders; however, with these advances come new questions. Given the long-term survival of patients with FL, drugs with favourable side-effect profile and minimal long-term risks are desired. FL is incurable with current treatment modalities. It often runs an indolent course with multiple relapses and progressively shorter intervals of remission. The identification of new targets and development of novel targeted therapies is imperative to exploit the biology of FL while inherently preventing relapse and prolonging survival. This review summarizes the growing body of knowledge regarding novel therapeutic targets, enabling the concept of individualized targeted therapy for the treatment of FL.

Available only for authorised users

Jemal A, Siegel R, Ward E: Cancer Statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.PubMed

Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998, 16 (8): 2780-95.PubMed

Harris NL, Jaffe ES, Diebold J: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999, 17 (12): 3835-49.PubMed

Schulz H, Bohlius JF, Trelle S: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Can Inst. 2007, 99: 706-14. 10.1093/jnci/djk152.

McLaughlin P, Grillo-López AJ, Link BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998, 16: 2825-33.PubMed

Lossos IS: Higher-grade transformation of follicular lymphoma -- a continuous enigma. Leukemia. 2005, 19 (8): 1331-3. 10.1038/sj.leu.2403801.PubMed

Wyllie AH, Kerr JFR, Currie AR: Cell death: the significance of apoptosis. Int Rev Cytol. 1980, 68: 251-10.1016/S0074-7696(08)62312-8.PubMed

Ashkenazi A, Dixit VM: Death Receptors- Signaling and Modulation. Science. 1998, 281: 1305-10.1126/science.281.5381.1305.PubMed

Creagh EM, Martin SJ: Capases: cellular demolition experts. Biochem Soc Trans. 2001, 29: 696-10.1042/BST0290696.PubMed

10.

Li P, Nijhawan D, Budihardjo I: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997, 91 (4): 479-89. 10.1016/S0092-8674(00)80434-1.PubMed

11.

Salvesen GS, Riedl SJ: Caspase Mechanisms. Adv Exp Med Biol. 2008, 615: 13-23. full_text.PubMed

12.

Sulston JE, Horvitz HR: Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. Dev Biol. 1977, 56 (1): 110-56. 10.1016/0012-1606(77)90158-0.PubMed

13.

Hengartner MO, Ellis RE, Horvitz HR: Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature. 1992, 356 (6369): 494-9. 10.1038/356494a0.PubMed

14.

Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988, 335 (6189): 440-21. 10.1038/335440a0.PubMed

15.

Cory S, Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002, 2 (9): 647-56. 10.1038/nrc883. ReviewPubMed

16.

Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ: A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J. 1995, 14 (22): 5589-96.PubMedCentralPubMed

17.

Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002, 2 (3): 183-92. 10.1016/S1535-6108(02)00127-7.PubMed

18.

Kelekar A, Thompson CB: Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 1998, 8 (8): 324-30. 10.1016/S0962-8924(98)01321-X.PubMed

19.

Huang DC, Adams JM, Cory S: The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J. 1998, 17 (4): 1029-39. 10.1093/emboj/17.4.1029.PubMedCentralPubMed

20.

Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH: Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA. 1995, 92 (17): 7834-8. 10.1073/pnas.92.17.7834.PubMedCentralPubMed

21.

Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 1993, 4 (6): 327-32.PubMed

22.

Yang E, Zha J, Jockel J: BAD, a heterodimeric partner for Bcl-XL and Bcl-2, displaces BAX and promotes cell death. Cell. 1995, 80 (2): 285-91. 10.1016/0092-8674(95)90411-5.PubMed

23.

Zha J, Harada H, Osipov K: BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem. 1997, 272 (39): 24101-4. 10.1074/jbc.272.39.24101.PubMed

24.

Acehan D, Jiang X, Morgan DG, Heuser JE: Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell. 2002, 9 (2): 423-432. 10.1016/S1097-2765(02)00442-2.PubMed

25.

Zou H, Li Y, Liu X, Wang X: An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999, 274 (17): 11549-56. 10.1074/jbc.274.17.11549.PubMed

26.

Fitch ME, Chang CM, Parslow TG: The BH3 domain is required for caspase-independent cell death induced by Bax and oligomycin. Cell Death Differ. 2000, 7 (4): 338-49. 10.1038/sj.cdd.4400659.PubMed

27.

Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984, 226 (4678): 1097-9. 10.1126/science.6093263.PubMed

28.

Bakshi A, Jensen JP, Goldman P: Cloning the chromosomal breakpoint of t(14;18) of human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Science. 1099, 226: 1097-1984.

29.

Klasa RJ: Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. Oncology (Williston Park). 2004, 18: 25-31.

30.

Reed JC, Stein C, Subasinghe C: Antisense-mediated inhibition of BCL2 proto-oncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 1990, 50: 6565-6570.PubMed

31.

O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A: Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2008, 26 (5): 820-

32.

Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S: Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004, 305 (5689): 1466-70. 10.1126/science.1099191.PubMedCentralPubMed

33.

Oh KJ, Barbuto S, Pitter K, Morash J, Walensky LD: A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro. J Biol Chem. 2006, 281 (48): 36999-7008. 10.1074/jbc.M602341200.PubMed

34.

Becattini B, Kitada S, Leone M: Rational design and real time in-cell detection of the pro-apoptotic activity of a novel compound targeting Bcl-Xl. Chem Biol. 2004, 11: 389-395. 10.1016/j.chembiol.2004.02.020.PubMed

35.

Sonenberg M, Huang JT, Ren YF, Su TL, Watanabe KA: Anti-fertility and other actions of gossypol analogues. Contraception. 1988, 37 (3): 247-55. 10.1016/0010-7824(88)90027-3.PubMed

36.

Zhai D, Jin C, Satterthwait AC, Reed JC: Comparison of chemical inhibitors of anti-apoptotic Bcl-2-family proteins. Cell Death Differ. 2006, 13: 1419-1421. 10.1038/sj.cdd.4401937.PubMed

37.

Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M: Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood. 2008, 111 (6): 3211-3219. 10.1182/blood-2007-09-113647.PubMedCentralPubMed

38.

Arnold AA, Aboukameel A, Chen J, Yang D, Wang S: Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. Mol Cancer. 2008, 7: 20-10.1186/1476-4598-7-20.PubMedCentralPubMed

39.

Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, al-Katib A: A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet. 1993, 70: 62-67. 10.1016/0165-4608(93)90132-6.PubMed

40.

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005, 435 (7042): 677-81. 10.1038/nature03579.PubMed

41.

van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006, 10 (5): 389-99. 10.1016/j.ccr.2006.08.027.PubMedCentralPubMed

42.

Cory S, Adams JM: Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell. 2005, 8 (1): 5-6. 10.1016/j.ccr.2005.06.012.PubMed

43.

Petros AM, Dinges J, Augeri DJ, Baumeister SA, Betebenner DA: Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem. 2006, 49 (2): 656-63. 10.1021/jm0507532.PubMed

44.

Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68 (9): 3421-8. 10.1158/0008-5472.CAN-07-5836.PubMed

45.

Elmore SW: ABT 263: an orally available bcl-2 family protein inhibitor. Proceedings AACR. 2007

46.

Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M: Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res. 2008, 14 (11): 3268-77. 10.1158/1078-0432.CCR-07-4622.PubMed

47.

Park CM, Bruncko M, Adickes J, Bauch J, Ding H: Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem. 2008, 51 (21): 6902-15. 10.1021/jm800669s. Epub 2008 Oct 8PubMed

48.

Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A: ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2008, 7 (10): 3265-74. 10.1158/1535-7163.MCT-08-0268.PubMed

49.

Wilson WH, Tulpule A, Levine AM: A phase 1/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with Refractory or Relapsed Lymphoid Malignancies. Blood (ASH Annual Meeting Abstracts). 2007, 110: 1371-

50.

Wang JL, Liu D, Zhang ZJ, Shan S, Han X: Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci. 2000, 97 (13): 7124-7129. 10.1073/pnas.97.13.7124.PubMedCentralPubMed

51.

Baell JB, Huang DCS: Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol. 2002, 64 (5-6): 851-63. 10.1016/S0006-2952(02)01148-6.PubMed

52.

Skommer J, Wlodkowic D, Mättö M, Eray M, Pelkonen J: HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk Res. 2006, 30 (3): 322-31. 10.1016/j.leukres.2005.08.022.PubMed

53.

Wlodkowic D, Skommer J, Pelkonen J: Multiparametric analysis of HA14-1-induced apoptosis in follicular lymphoma cells. Leuk Res. 2006, 30 (9): 1187-92. 10.1016/j.leukres.2005.11.024.PubMed

54.

Wlodkowic D, Skommer J, Pelkonen J: Brefeldin A triggers apoptosis associated with mitochondrial breach and enhances HA14-1- and anti-Fas-mediated cell killing in follicular lymphoma cells. Leuk Res. 2007, 31 (12): 1687-700. 10.1016/j.leukres.2007.03.008.PubMed

55.

Fridman JS, Lowe SW: Control of apoptosis by p53. Oncogene. 2003, 22 (56): 9030-40. 10.1038/sj.onc.1207116.PubMed

56.

Hainaut P, Hollstein M: p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000, 77: 81-137. full_text.PubMed

57.

Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000, 408 (6810): 307-10. 10.1038/35042675.PubMed

58.

Shangary S, Wang S: Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008, 14 (17): 5318-24. 10.1158/1078-0432.CCR-07-5136.PubMedCentralPubMed

59.

Feki A, Irminger-Finger I: Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol. 2004, 52 (2): 103-16. 10.1016/j.critrevonc.2004.07.002.PubMed

60.

Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992, 69: 1237-45. 10.1016/0092-8674(92)90644-R.PubMed

61.

Fakharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991, 10: 1565-69.PubMedCentralPubMed

62.

Fakharzadeh SS, Rosenblum-Vos L, Murphy M, Hoffman EK, George DL: Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene. Genomics. 1993, 15: 283-90. 10.1006/geno.1993.1058.PubMed

63.

Jones SN, Roe AE, Donehower LA, Bradley A: Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995, 378: 206-8. 10.1038/378206a0.PubMed

64.

Montes de Oca Luna R, Wagner DS, Lozano G: Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995, 378: 203-6. 10.1038/378203a0.PubMed

65.

Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME: mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol. 2003, 23: 462-72. 10.1128/MCB.23.2.462-473.2003.PubMedCentralPubMed

66.

Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996, 274: 948-53. 10.1126/science.274.5289.948.PubMed

67.

Vassilev LT: Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle. 2004, 3: 419-21.PubMed

68.

Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S: Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 2006, 49: 3432-35. 10.1021/jm051122a.PubMed

69.

Shangary S, Qin D, McEachern D, Liu M, Miller RS: Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA. 2008, 105 (10): 3933-8. 10.1073/pnas.0708917105.PubMedCentralPubMed

70.

Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM: mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol. 2003, 23 (2): 462-72. 10.1128/MCB.23.2.462-473.2003.PubMedCentralPubMed

71.

Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI: Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell. 2006, 10: 501-14. 10.1016/j.ccr.2006.10.010.PubMed

72.

Adams J: Development of the proteasome inhibitor PS-341. Oncologist. 2002, 7: 9-16. 10.1634/theoncologist.7-1-9.PubMed

73.

Ciechanover A: The ubiquitin-proteasome proteolytic pathway. Cell. 1994, 79: 13-21. 10.1016/0092-8674(94)90396-4.PubMed

74.

Varshavsky A: The ubiquitin system. Trend Biochem Sci. 1997, 22: 383-387. 10.1016/S0968-0004(97)01122-5.PubMed

75.

Orlowski M: The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry. 1990, 29: 10289-10297. 10.1021/bi00497a001.PubMed

76.

Coux O, Tanaka K, Goldberg AL: Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996, 65: 801-847. 10.1146/annurev.bi.65.070196.004101.PubMed

77.

Almond JB, Cohen GM: The proteasome: A novel target for cancer chemotherapy. Leukemia. 2002, 16: 433-443. 10.1038/sj.leu.2402417.PubMed

78.

An B, Goldfarb RH, Siman R: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 1998, 5: 1062-1075. 10.1038/sj.cdd.4400436.PubMed

79.

Orlowski RZ, Eswara JR, Lafond-Walker A: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 1998, 58: 4342-4348.PubMed

80.

Adams J, Kauffman M: Development of the proteasome inhibitor velcade (bortezomib). Cancer Invest. 2004, 22: 304-11. 10.1081/CNV-120030218.PubMed

81.

Adams J, Palombella VJ, Elliott PJ: Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 2000, 18: 109-21. 10.1023/A:1006321828515.PubMed

82.

DeMartino GN, Slaughter CA: The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem. 1999, 274: 22123-6. 10.1074/jbc.274.32.22123.PubMed

83.

Kisselev AF, Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001, 8: 739-58. 10.1016/S1074-5521(01)00056-4.PubMed

84.

Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59: 2615-22.PubMed

85.

Myung J, Kim KB, Crews CM: The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev. 2001, 21: 245-73. 10.1002/med.1009.PubMedCentralPubMed

86.

Matta H, Chaudhary PM: The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther. 2005, 4: 77-82. 10.4161/cbt.4.1.1379.PubMed

87.

An J, Sun Y, Fisher M, Rettig MB: Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia. 2004, 18: 1699-704. 10.1038/sj.leu.2403460.PubMed

88.

Maharaj L, Strauss S, Stec J, Lister T, Joel S: Mantle cell and follicular lymphoma samples demonstrate differeing sensitivity to bortezomib in a primary culture system. Blood. 2004, 104: 900-

89.

Pham L, Tamayo AT, Lo P, Yoshimura L, Ford R: Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood. 2001, 98: 465-

90.

Goy A, Remache Y, Barkoh B, Jiang Y, Hart S, Gilles F: Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin's lymphoma cells. Blood. 2004, 104: 389a-90a.

91.

Goy A, Bernstein S, Kahl B, Epner E, Leonard JP, Stadtmauer E, Morgan D, Belt R, Baidas S, Fisher RI: Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study. J Clin Oncol. 2005, 23: 6563-10.1200/JCO.2005.03.108.

92.

O'Connor O, Wright J, Moskowitz C, MacGregor-Cortelli B, Straus D, Evans A, Winter J, Koc O, Horvath N, Blumel S, Vose J, Schenkein D: A multicenter experience with single agent bortezomib in non-Hodgkin's lymphoma reveals marked differences in sub-type sensitivity to proteasome inhibition. Blood. 2004, 104: 175-

93.

Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005, 23: 667-75. 10.1200/JCO.2005.03.108.PubMed

94.

Strauss SJ, Maharaj L, Stec J, Boral A, Trehu E, Schenkein D, Johnson P, Joel SP, TA L: Phase II clinical study of bortezomib (velcade) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). Blood. 2004, 104: 10.1182/blood-2004-04-1311.

95.

Sheridan JP, Marsters SA, Pitti RM: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997, 277: 818-821. 10.1126/science.277.5327.818.PubMed

96.

Thornberry NA, Lazebnik Y: Caspases: Enemies within. Science. 1998, 281: 1312-1316. 10.1126/science.281.5381.1312.PubMed

97.

Halpern W, Lincoln C, Sharifi A: Variable distribution of TRAIL Receptor 1 in primary human tumor and normal tissues. Eur J Cancer. 2004, 2: 69-

98.

Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P: Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol. 2005, 175 (9): 5586-90.PubMed

99.

Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ: Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res. 2003, 9 (10 Pt 1): 3731-41.PubMed

100.

Kim H, Morgan DE, Zeng H, Grizzle WE, Warram JM: Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology. 2008, 248 (3): 844-51. 10.1148/radiol.2483071740.PubMedCentralPubMed

101.

Travert M, Ame-Thomas P, Pangault C, Morizot A, Micheau O: CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol. 2008, 181 (2): 1001-11.PubMed

102.

Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A: Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol. 2007, 25 (29): 4701-10.1200/JCO.2007.14.0996.

103.

Younes A, Vose JM, Zelenetz AD: Results of a Phase 2 trial of HGS-ETR1(agonist human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL). Blood. 2005, 106: 146-

104.

Wagner KW, King F, Nomoto K, Knee DA, Hampton G, Nasoff M, Deveraux QL: "Activation and suppression of the TRAIL death-receptor pathway in chemotherapy sensitive and resistant follicular lymphoma cells". Cancer Biol Ther. 2003, 2 (5): 534-540.PubMed

105.

Padhye S, Banerjee S, Ahmad A, Mohammad R, Sarkar FH: From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. Cancer Ther. 2008, 6 (b): 495-510.PubMedCentralPubMed

106.

Al-Ali A, Alkhawajah AA, Randhawa MA, Shaikh NA: Oral and intraperitoneal LD50 of thymoquinone, an active principle of Nigella sativa, in mice and rats. J Ayub Med Coll Abbottabad. 2008, 20 (2): 25-7.PubMed

107.

Shoieb AM, Elgayyar M, Dudrick PS, Bell JL, Tithof PK: In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int J Oncol. 2003, 22: 107-113.PubMed

108.

Hartwell LH, Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science. 1989, 246: 629-634. 10.1126/science.2683079.PubMed

109.

Hartwell LH, Kastan MB: Cell cycle control and cancer. Science. 1994, 266: 1821-1828. 10.1126/science.7997877.PubMed

110.

Gali-Muhtasib HU, bou Kheir WG, Kheir LA, Darwiche N, Crooks PA: Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anticancer Drugs. 2004, 15: 389-399. 10.1097/00001813-200404000-00012.PubMed

111.

el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell. 1993, 75: 817-825. 10.1016/0092-8674(93)90500-P.PubMed

112.

Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991, 352: 345-347. 10.1038/352345a0.PubMed

113.

Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA. 1992, 89: 4495-4499. 10.1073/pnas.89.10.4495.PubMedCentralPubMed

114.

Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1997, 1: 3-11. 10.1016/S1097-2765(00)80002-7.PubMed

115.

Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998, 282: 1497-1501. 10.1126/science.282.5393.1497.PubMed

116.

Roepke M, Diestel A, Bajbouj K, Walluscheck D, Schonfeld P, Roessner A, Schneider-Stock R, Gali-Muhtasib H: Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol Ther. 2007, 6: 160-169. 10.4161/cbt.6.2.3575.PubMed

117.

Yamasaki L: Role of the RB tumor suppressor in cancer. Cancer Treat Res. 2003, 115: 209-239. full_text.PubMed

118.

119.

El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA: Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int J Cancer. 2005, 117: 409-417. 10.1002/ijc.21205.PubMed

120.

Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP, Reddy GP: Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 2007, 67: 7782-7788. 10.1158/0008-5472.CAN-07-1483.PubMed

121.

Aggarwal BB, Kunnumakkara AB, Harikumar KB, Tharakan ST, Sung BA: Potential of Spice-Derived Phytochemicals for Cancer Prevention. Planta Med. 2008, 74 (13): 1560-9. 10.1055/s-2008-1074578.PubMed

122.

Sethi G, Ahn KS, Aggarwal BB: Targeting Nuclear Factor-{kappa}B Activation Pathway by Thymoquinone: Role in Suppression of Antiapoptotic Gene Products and Enhancement of Apoptosis. Mol Cancer Res. 2008, 6: 1059-1070. 10.1158/1541-7786.MCR-07-2088.PubMed

123.

Sethi G, Ahn KS, Aggarwal BB: Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res. 2008, 6 (6): 1059-70. 10.1158/1541-7786.MCR-07-2088.PubMed

124.

Chehl N, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA: Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford). 2009, 11 (5): 373-81.

125.

Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM: Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res. 2009, 69 (13): 5575-83. 10.1158/0008-5472.CAN-08-4235.PubMed

126.

Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, Sethi G, Aggarwal BB, Liu M: Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther. 2008, 7 (7): 1789-96. 10.1158/1535-7163.MCT-08-0124.PubMedCentralPubMed

127.

Gali-Muhtasib H, Kuester D, Mawrin C, Bajbouj K, Diestel A, Ocker M, Habold C, Foltzer-Jourdainne C, Schoenfeld P, Peters B, ab-Assaf M, Pommrich U, Itani W, Lippert H, Roessner A, Schneider-Stock R: Thymoquinone Triggers Inactivation of the Stress Response Pathway Sensor CHEK1 and Contributes to Apoptosis in Colorectal Cancer Cells. Cancer Res. 2008, 68: 5609-5618. 10.1158/0008-5472.CAN-08-0884.PubMed

Title: New targets for the treatment of follicular lymphoma
Authors: Nishant Tageja
Subhash Padheye
Prasad Dandawate
Ayad Al-Katib
Ramzi M Mohammad
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2009
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-2-50

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs

RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression

Adult B lymphoblastic leukaemia/lymphoma with hypodiploidy (-9) and a novel chromosomal translocation t(7;12)(q22;p13) presenting with severe eosinophilia – case report and review of literature

An unusual presentation of precursor T cell lymphoblastic leukemia/lymphoma with cholestatic jaundice: case report

Update in the management of chronic lymphocytic leukemia

Mechanism of action of lenalidomide in hematological malignancies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer